11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation

The induction of neuroinflammatory processes, characterized by upregulation of the peripheral benzodiazepine receptor (PBR) expressed by microglial cells, is well correlated with neurodegenerative diseases and with acute neuronal loss. The continually increasing incidence of neurodegenerative diseases in developed countries has become a major health problem, for which the development of diagnostic and follow-up tools is required. Here we investigated a new PBR ligand suitable for PET to monitor neuroinflammatory processes as an indirect hallmark of neurodegeneration. Methods: We compared PK11195, the reference compound for PBR binding sites, with the new ligand DPA-713 (N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide), using a small-animal dedicated PET camera in a model of neuroinflammation in rats. Seven days after intrastriatal injection of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), a PET scan was performed using 11C-PK11195 or 11C-DPA-713. Immunohistochemistry for neuronal (NeuN), astrocyte (glial fibrillary acidic protein), and microglial (CD11) specific markers as well as 3H-PK11195 autoradiographic studies were then correlated with the imaging data. Results: Seven days after a unilateral injection of AMPA in the striatum, 11C-DPA-713 exhibits a better contrast between healthy and damaged brain parenchyma than 11C-PK11195 (2.5-fold ± 0.14 increase vs. 1.6-fold ± 0.05 increase, respectively). 11C-DPA-713 and 11C-PK11195 exhibit similar brain uptake in the ipsilateral side, whereas, in the contralateral side, 11C-DPA-713 uptake was significantly lower than 11C-PK11195. Modeling of the data using the simplified reference tissue model shows that the binding potential was significantly higher for 11C-DPA-713 than for 11C-PK11195. Conclusion: 11C-DPA-713 displays a higher signal-to-noise ratio than 11C-PK11195 because of a lower level of unspecific binding that is likely related to the lower lipophilicity of 11C-DPA-713. Although further studies in humans are required, 11C-DPA-713 represents a suitable alternative to 11C-PK11195 for PET of PBR as a tracer of neuroinflammatory processes induced by neuronal stress.

[1]  R. Tanzi,et al.  The genetic epidemiology of neurodegenerative disease. , 2005, The Journal of clinical investigation.

[2]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[3]  F. Turkheimer,et al.  Towards a transcriptome definition of microglial cells , 2004, Neurogenetics.

[4]  N L Foster,et al.  PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  C. Wiessner,et al.  Time course of microglia activation and apoptosis in various brain regions after permanent focal cerebral ischemia in mice , 1998, Acta Neuropathologica.

[6]  G. Fur,et al.  Labelling of “Peripheral‐Type” Benzodiazepine Binding Sites in the Rat Brain By Using [3H]PK 11195, an Isoquinoline Carboxamide Derivative: Kinetic Studies and Autoradiographic Localization , 1983, Journal of neurochemistry.

[7]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[8]  Yuji Nagai,et al.  Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain , 2004, Synapse.

[9]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[10]  Hyun B Choi,et al.  Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum , 2005, Neurobiology of Disease.

[11]  Alan C. Evans,et al.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis , 1997, Journal of neuroscience research.

[12]  B. Kiss,et al.  PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects , 2002, Acta neurologica Scandinavica.

[13]  Ryuji Nakao,et al.  Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Biegon,et al.  Region‐selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain , 2002, Journal of neurochemistry.

[15]  D. Graham,et al.  Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[16]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[17]  F. Fazio,et al.  Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo pet imaging of neurodegeneration , 2004, Neurochemistry International.

[18]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[19]  B. Gulyás,et al.  [11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies , 2005, Journal of the Neurological Sciences.

[20]  N. Rothwell,et al.  Sixteenth Gaddum Memorial Lecture December 1996. Neuroimmune interactions: the role of cytokines , 1997, British journal of pharmacology.

[21]  Tetsuya Suhara,et al.  Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. , 2004, Journal of medicinal chemistry.

[22]  Ronald Boellaard,et al.  Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  S. Meikle,et al.  Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. , 2005, Bioorganic & medicinal chemistry.

[24]  K. Hossmann,et al.  Monitoring the temporal and spatial activation pattern of astrocytes in focal cerebral ischemia using in situ hybridization to GFAP mRNA: comparison withsgp-2 andhsp70 mRNA and the effect of glutamate receptor antagonists , 1996, Brain Research.

[25]  R. Dempsey,et al.  Up‐regulation of the peripheral‐type benzodiazepine receptor expression and [3H]PK11195 binding in gerbil hippocampus after transient forebrain ischemia , 2001, Journal of neuroscience research.

[26]  A. Gee,et al.  The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. , 2003, Nuclear medicine and biology.

[27]  D. Schober,et al.  Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  Jean-Claude Baron,et al.  In Vivo Mapping of Brain Benzodiazepine Receptor Changes by Positron Emission Tomography After Focal Ischemia in the Anesthetized Baboon , 1993, Stroke.

[29]  R B Banati,et al.  Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195 , 2000, Neurology.

[30]  S. Kohsaka,et al.  Microglia: neuroprotective and neurotrophic cells in the central nervous system. , 2004, Current drug targets. Cardiovascular & haematological disorders.

[31]  Tetsuya Suhara,et al.  [(11)C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. , 2003, Nuclear medicine and biology.

[32]  C. Martini,et al.  2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. , 2001, Bioorganic & medicinal chemistry.

[33]  M. Grégoire,et al.  Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C]methyl triflate. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[34]  David K. Menon,et al.  Intrinsic Activated Microglia Map to the Peri-infarct Zone in the Subacute Phase of Ischemic Stroke , 2006, Stroke.

[35]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[36]  J. Bénavidès,et al.  In vivo labelling in several rat tissues of 'peripheral type' benzodiazepine binding sites. , 1984, European journal of pharmacology.

[37]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[38]  J C Baron,et al.  Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. , 1991, European journal of pharmacology.

[39]  André Syrota,et al.  Synthesis of N‐(11C) methyl, N‐(methyl‐1 propyl), (chloro‐2 phenyl)‐1 isoquinoleine carboxamide‐3 (PK 11195): A new ligand for peripheral benzodiazepine receptors , 1984 .

[40]  R Myers,et al.  The distribution of radioactivity in brains of rats given [N-methyl-11C]PK 11195 in vivo after induction of a cortical ischaemic lesion. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.